Case report

Ampicillin plus ceftriaxone therapy against Enterococcus faecalis endocarditis: A case report, guidelines considerations, and literature review

Andrea Marino\textsuperscript{a,b,⁎}, Antonio Munafò\textsuperscript{c,d}, Aldo Zagami\textsuperscript{a}, Manuela Ceccarelli\textsuperscript{a}, Edoardo Campanella\textsuperscript{a,b}, Federica Cosentino\textsuperscript{a,b}, Vittoria Moscatt\textsuperscript{a,b}, Giuseppina Cantarella\textsuperscript{c,d}, Rosaria Di Mauro\textsuperscript{c,d}, Renato Bernardini\textsuperscript{c,d}, Giuseppe Nunnari\textsuperscript{b}, Bruno Cacopardo\textsuperscript{a}

\textsuperscript{a} Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Nesima Hospital, University of Catania, Catania, Italy
\textsuperscript{b} Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
\textsuperscript{c} Department of Biomedical and Biotechnological Science, School of Medicine, University of Catania, 95123 Catania, Italy
\textsuperscript{d} Unit of Clinical Toxicology, Policlinico G. Rodolico, School of Medicine, University of Catania, 95123 Catania, Italy

Keywords: Infective endocarditis Enterococcus faecalis Double beta-lactams therapy Ampicillin plus ceftriaxone Antibiotics resistance

Introduction

Enterococcus faecalis infective endocarditis (EFIE) is a major clinical problem, accounting for the third most frequent cause of both native and prosthetic valve IE in the community and for the second cause of healthcare-associated infective endocarditis (HAIES) \cite{1,2}. In the last two decades, this disease has become increasingly prevalent among the elderly and patients with relevant comorbidities, making the treatment of this infection particularly difficult and keeping mortality rates stable \cite{3,4}. The lack of reliable bactericidal activity of most antimicrobials, the renowned nephrotoxicity arising from the synergistic therapeutic combination of beta-lactams and aminoglycosides, and the widespread development of high-level aminoglycosides resistance (HLAR), pose challenges to obtaining a favorable clinical outcome \cite{5,6}. This scenario has prompted efforts to identify different pharmaceutical effective solutions for the treatment of EFIE \cite{7}.

In vitro and in vivo experimental studies reported synergism of dual beta-lactam combination against clinical strains of E. faecalis, regardless of their susceptibility to aminoglycosides \cite{8,9}. Specifically, the basis for the synergistic activity of double beta-lactam combination appears to be related to the differential and complementary saturation of E. faecalis Penicillin-binding proteins (PBPs), thus generating the necessary bactericidal effect \cite{10,11}. Thereafter, clinical evidence supported these experimental results, leading to an update of EFIE treatment guidelines.

Here, we report the case of a patient with prosthetic EFIE treated with dual beta-lactams combination therapy and discuss this therapeutic challenge, along with literature evidence.

Case description

A 68-year-old woman was brought to the hospital with 7 days of high fever (up to 40 °C) associated with intense asthenia and malaise.
Three months prior, due to a severe and symptomatic aortic stenosis, the patient underwent aortic valve replacement with a biological prosthesis.

Her medical history showed hypertension and smoking. Family history was significant for heart diseases. She took aspirin, ace-inhibitors, beta-blockers, and diuretics.

On admission, she was febrile (T: 38 °C), blood pressure was 130/80 mmHg, heart rate was 90 bpm, oxygen saturation in room air was 97%, respiratory rate was 18 breaths/min.

Physical examination displayed a systolic heart murmur in the aortic auscultation site; her blood test revealed normal white blood cell count (6.8 × 10^9/mm^3), mild anemia with hemoglobin level of 12 g/dl, normal platelets count (165 × 10^9/mm^3). Her inflammatory markers were elevated: CRP was 10 mg/dl (normal range < 0.5 mg/dl), ESR was 80 mm/h (normal range < 10 mm/h), Procalcitonin was negative. Creatinine was 0.7 mg/dl (eGFR with CKD-EPI was 89 ml/min). Normal liver markers (AST, ALT, bilirubin, INR). HIV, HBV, and HCV serology tested negative. SARS-CoV2 test was negative [12,13].

Three sets of blood cultures and urine cultures were performed and then a Transesophageal Echocardiogram (TEE) followed by a Transesophageal Echocardiogram (TEE) were obtained which showed a small vegetation (< 1 cm) on the aortic prosthetic valve.

Empiric antibiotic therapy was started with ampicillin/sublactam 3 g three times daily IV, with an infusion time of at least 3 h, plus gentamicin 12 g/dl in single administration IV as well as daptomycin 10 mg/kg daily IV.

After two days, fever still persisted and inflammatory markers were higher (CRP 19 mg/dl); procalcitonin was negative. Urine culture was negative. All sets of blood cultures, taken on admission, resulted positive for Enterococcus faecalis resistant to aminoglycosides (resistance pattern as shown in Table 1). Colonoscopy did not show any pathological lesions to justify enterococcal bacteremia. Respiratory pathogen panel test (BIOFIRE Respiratory 2.1 Panel) tested negative for viral superinfections. Moreover, the patient exhibited high levels of CPK (342 U/L, with a normal range of 20–180 U/L) along with an increased creatinine value (1 mg/dl, eGFR was 58 ml/min).

Because of the antibiogram and blood tests results, daptomycin was stopped together with gentamicin. We thus initiated ceftiraxone 2 g every 12 h along with ampicillin/sublactam at the previous dosage.

In the 72 h following the new antibiotic treatment, fever disappeared, inflammatory markers started decreasing (CRP 10.5 mg/dl), and blood cultures taken 48 h apart tested negative. Renal function improved (eGFR up to 80 ml/min) and CPK levels decreased (206 U/L).

We continued ampicillin plus ceftiraxone therapy for 6 weeks after the change in antibiotic regimen, obtaining gradual inflammatory markers decline, clinical improvement and, especially, a new TTE that revealed the dissolution of the vegetation on the prosthetic valve. The patient was then discharged.

Follow-up at 6 months performed with blood tests and TEE showed further amelioration of inflammatory markers and confirmed the dissolution of the vegetation.

**Discussion**

Ampicillin plus ceftiraxone (AC) is the combination of choice for HLAR E. faecalis IE and, together with ampicillin plus gentamicin (AG), is one of the two preferred regimes against non-HLAR EIEF [14].

Several studies showed that the typical EIEF patient is elderly, presenting more comorbidities (especially chronic renal failure) than other etiologies IE patient; because of that, non-aminoglycoside-based regimens were tested, mainly due to possible nephrotoxic complications of prolonged aminoglycoside administration [15,16]. Furthermore, even though aminoglycoside-based regimens have been the first choice for EIEF since the 1950s, the growing prevalence of aminoglycoside-resistant strains has required different therapeutic approaches [17,18].

Synergistic findings between ampicillin and ceftiraxone against HLAR E. faecalis were reported by Gavalda et al., suggesting that the association with ceftiraxone extends the range of ampicillin’s bactericidal concentrations [9]. These findings confirmed the work of Mainardi et al. about in vitro synergy between amoxicillin and cefotaxime against strains of E. faecalis, showing the decrease in MIC values for amoxicillin in the presence of cefotaxime and vice versa [8], which is explained by the differential targeting of the PBPs by different beta-lactams, with significant synergism against E. faecalis cell wall synthesis [19].

An observational, multicenter, open-label clinical trial conducted by Gavalda et al. showed a clinical cure rate of 67.4% as regards the treatment with ampicillin (2 g every 4 h) plus ceftiraxone (2 g every 12 h) in patients with EIEF, regardless of the presence of HLAR strains, and a treatment-related mortality rate in HLAR EIEF patients of 28.6% (comparable to those reported in previous studies). Furthermore, only 2 patients had treatment-related side effects, but nephrotoxicity was not observed. Despite limitations, this study provided evidence that supports the use of double beta-lactam combination as an effective treatment for patients with HLAR EIEF and, in addition, as a wise option for patients at high risk of developing nephrotoxicity, regardless of strain susceptibility [20].

With the goal of assessing the efficacy and safety of ampicillin plus ceftiraxone combination in the treatment of EIEF compared with ampicillin plus an aminoglycoside, Fernandez-Hidalgo et al. conducted a large, non-randomized, non-blinded, comparative, multicenter cohort study including 87 patients treated with ampicillin plus gentamicin (A + G) and 159 patients treated with ampicillin plus ceftiraxone (A + C). The authors found no differences in mortality, clinical failure, or relapse rates between the two treatment arms during treatment or at 3 months of follow-up, even though A + C-treated patients were in poorer general condition before acquiring the infection than A + G patients. As for adverse events, owing to renal impairment, a higher proportion of A + G patients switched or stopped gentamicin due to renal failure and did not receive the complete course of aminoglycoside-containing regimen. Despite limitations given by retrospective data collection, the lack of a random assignment and the liberal and misleading definition of acute renal failure, with the interruption of aminoglycoside therapy left to the physicians’ choice, this study provided useful clinical data to support the use of A+C regimen for the treatment of EIEF [21].

Pericas et al. conducted a monocenter retrospective analysis of prospective cohort of EIEF patients treated from 1997 to 2011 which showed, similarly to Fernandez-Hidalgo et al., no significant difference in in-hospital mortality (27% vs 23%), 1-year mortality (29% vs...
The combination of ampicillin and ceftriaxone is effective and safe for treating HLAR EFIE and non-HLAR EFIE, irrespective of aminoglycoside susceptibility. The clinical data evaluating the usefulness of A+C regimen are summarized in Table 2.

**Conclusion**

The case we reported shows the clinical management of a prosthetic valve infective endocarditis caused by a HLAR *E. faecalis* strain, which was successfully treated with ampicillin plus ceftriaxone, despite the presence of prosthetic valve and the patient's severe clinical conditions. Furthermore, our patient developed an eGFR reduction probably because of both gentamicin administration and severe infection, as reported in the case series we cited. Although daptomycin represented a valid option to administer as shown on the antibiogram, since the patient had an increase of CPK levels and in order to avoid further renal injuries, we were forced to stop daptomycin infusion and replace it with ceftriaxone. The patient tolerated the dual beta-lactam therapy with no adverse drug reaction, achieving a rapid bacterial clearance on blood cultures and amelioration of inflammation marker levels. Despite the fact that we were forced to switch the antibiotic therapy, our case summarizes the two main indications for the dual beta-lactam combination with ampicillin and ceftriaxone for EFIE, including high risk of impaired kidney function due to aminoglycoside therapy and detection of Enterococcal strain with aminoglycoside resistance (HLAR strains), in spite of rapid microbiological diagnosis, antimicrobial susceptibility testing, and elimination of possible adverse drug reactions. Furthermore, on the basis of susceptibility data, especially on the ampicillin higher MIC than ampicillin/sulbactam or amoxicillin/clavulanate, it is possible to speculate that this *E. faecalis* was also a penicillinases producer.

This case highlights that it is essential to consider an antibiotic's pharmacodynamic and pharmacokinetic properties in order to choose the most advantageous antibiotics, and not just the antibiogram, to treat challenging infections such as prosthetic valve endocarditis. For instance, the beta lactam time-dependent mechanism of action, which had been optimized by prolonging the infusion time for ampicillin/sulbactam (3 h) and increasing the dosage of ceftriaxone (2 g twice daily), and the synergistic action of both beta lactam antibiotics. Moreover, the epidemiological changes of EFIE with ageing and frail populations, and an

---

**Table 2**

| Author                  | Title                                                                                     | Subjects                                                                 | Regimen                                                                 | Method                                                                 | Main findings                                      |
|-------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------|
| Gavaldà et al. [20]     | Brief Communication: Treatment of Enterococcus faecalis native valve endocarditis with Ampicillin plus Ceftriaxone (2 g q12h) | 43 patients with E. faecalis EFIE                                        | A + G, Ampicillin plus Ceftriaxone                                      | Observational, open label, non-randomized, multicenter clinical trial observing outcomes in patients with E. faecalis EFIE | Significantly in recent years that alternative regimens are becoming more acceptable in patients with E. faecalis EFIE. The combination of A + C is effective and safe for treating HLAR EFIE and non-HLAR EFIE, irrespective of aminoglycoside susceptibility. |
underestimation of treatment side-effects, namely the high risk of nephrotoxicity, should force a paradigm shift in the antibiotic choice.

**CRedit authorship contribution statement**

AM and AM wrote the paper. AZ, EC, FC, VM and MC gave clinical assistance to the case. RDM and GC searched literature references. RB, GN and BC revised the paper. All authors read and approved the final manuscript.

**Ethical approval**

Not applicable.

**Consent**

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

**Conflicts of Interest**

The authors declare no conflict of interest.

**Acknowledgments**

The authors would like to thank Dr. Pietro Leanza for his kind English revision of the manuscript.

**Funding**

This manuscript received no external funding.

**References**

[1] JM M, JM P, del RA. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question!. Circulation 2013;127(17):1763–6. https://doi.org/10.1161/CIRCULATIONAHA.112.001241.

[2] Fernández-Hidalgo N, Escolá-Vergé L, Pericàs JM. Enterococcus faecalis endocarditis: what's next?. Vol. 15(5); 2020, p. 349–64. (https://doi.org/10.2217/FMB-2019-0247).

[3] Chirozu C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the international collaboration on endocarditis-prospective cohort study. Clin Microbiol Infect 2013;19(12):1140–7. https://doi.org/10.1111/j.1469-0691.2012.04199.x.

[4] Mcdonald JR, Olaison L, Anderson D, Hoen B, Miro JM, Ekyohn S, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005;118(7):759–66. https://doi.org/10.1016/j.amjmed.2005.02.010.

[5] CB R, MS R, NW L, CW S, WR W, JM S. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis 1996;173(4):909–13. https://doi.org/10.1093/INFIDIS/173.4.909.

[6] Murdoch DR. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169(5):463–73. https://doi.org/10.1001/archinternmed.2008.603.

[7] CA A, GA C, BE M. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16(6):555–62. https://doi.org/10.1111/j.1469-0691.2010.03214.x.

[8] Mainardi JL, Gutmann L, Acaf JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995;39(9):1984–7. https://doi.org/10.1128/AAC.39.9.1984.

[9] Gavalda J, Torres C, Tenorio C, López P, Zaragoza M, Capdevila JA, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999;43(2):639–46. https://doi.org/10.1128/aac.43.2.639.

[10] Baddour LM, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132:1345–86. https://doi.org/10.1161/CIR.0000000000000296.

[11] Habib G, et al. 2015 ESC Guidelines for the management of infective endocarditis. European Heart J, Vol. 36(44); 2015, p. 3075–123. (https://doi.org/10.1093/eurheartj/ehv319).

[12] Colesia BM, Marino A, Del Vecchio BF, Bruno R, Palermo F, Gusino M, et al. Is it safe and cost saving to defer the CD4+ cell count monitoring in stable patients on art with more than 350 or 500 cells/μl?. Mediterr J Hematol Infect Dis 2019;11(1):e2019063. https://doi.org/10.4084/MJHID.2019.063. [PMID: 31070588; PMCID: PMC6287665].

[13] Marino A, Pampaloni A, Scuderi D, Cosentino F, Moscatt V, Ceccarelli M, et al. High-flow nasal cannula oxygenation and tocilizumab administration in patients critically ill with COVID-19: a report of three cases and a literature review. World Acad Sci J 2020;2. https://doi.org/10.3892/was.2020.0423-1-21.

[14] Marino A, Munafò A, Zagami A, Ceccarelli M, Di Mauro R, Cantarella G, et al. Ampicillin plus ceftriaxone regimen against Enterococcus faecalis endocarditis: a literature review. J Clin Med 2021;10(19):4594. https://doi.org/10.3390/JCM10194594.

[15] Dahl A, Rasmussen RV, Bundgaard H, Hassager C, Bruun LE, Lauridsen TK, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013;127(17):1810–7. https://doi.org/10.1161/CIRCULATIONAHA.112.012170.

[16] Pericàs JM, Cervera C, Moreno A, García-de-la-María C, Almela M, Falces C, et al. Outcome of Enterococcus faecalis infective endocarditis according to the length of antibiotic therapy: preliminary data from a cohort of 78 patients. PLoS One 2013;8(3):e592387. https://doi.org/10.1371/JOURNAL.PONE.0192387.

[17] El-Sokkary R, Uysal S, Eredem H, Kullar R, Peköz AU, Amer F, et al. Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: an international ID-IIR survey. Eur J Clin Microbiol Infect Dis 2021;40(11):2323–34. https://doi.org/10.1007/s00108-021-04209-1. Epub 2021 Jun 21. PMID: 34155547.

[18] Eredem H, Hargreaives S, Ankarali H, Caskurlu H, Ceviker SA, Bahar-Kacmaz A, et al. Managing adult patients with infectious diseases in emergency departments: international ID-IIR study. J Comermed butter 2021;33(5):302–18. https://doi.org/10.1001/2020.09.01836196. Epub 2021 Mar 18. PMID: 33734040.

[19] MB R, LB R, CA A, MJ R, RL A. A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis 2018;67(2):303–9. https://doi.org/10.1093/CID/CY064.

[20] Gavalda J, Len O, Miro JM, Muñoz P, Montejo M, Alarcón A, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Antimicrob Agents Chemother 1999;43(3):639–46. https://doi.org/10.1128/AAC.43.3.639.

[21] Baddour LM, Wilson WR, Bayer AS, Jr Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective Endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation 2015;132(15):1435–86. https://doi.org/10.1161/10.CIR.0000000000000296.

[22] El Rafie A, DeSimone DC, Narichania AD, Sohail MR, Vikram HR, Li Z, et al. Comparison of dual β-lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis. J Infect 2018;77(5):398–404. https://doi.org/10.1016/j.jinf.2018.06.013.

[23] Ramos-Martínez A, Pericàs JM, Fernández-Cruz A, Muñoz P, Valero M, Kestler M, et al. Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: a prospective cohort study. PLoS One 2020;15(8):e0237011. https://doi.org/10.1371/JOURNAL.PONE.0237011.